Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outset Medical (OM) Work In Process (2019 - 2025)

Outset Medical (OM) has disclosed Work In Process for 7 consecutive years, with $7.3 million as the latest value for Q4 2025.

  • Quarterly Work In Process fell 26.64% to $7.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.3 million through Dec 2025, down 26.64% year-over-year, with the annual reading at $7.3 million for FY2025, 26.64% down from the prior year.
  • Work In Process for Q4 2025 was $7.3 million at Outset Medical, down from $7.5 million in the prior quarter.
  • The five-year high for Work In Process was $13.9 million in Q3 2024, with the low at $6.1 million in Q4 2021.
  • Average Work In Process over 5 years is $9.4 million, with a median of $9.3 million recorded in 2022.
  • The sharpest move saw Work In Process surged 163.81% in 2021, then crashed 46.24% in 2025.
  • Over 5 years, Work In Process stood at $6.1 million in 2021, then soared by 50.08% to $9.1 million in 2022, then dropped by 3.94% to $8.7 million in 2023, then grew by 14.26% to $10.0 million in 2024, then fell by 26.64% to $7.3 million in 2025.
  • According to Business Quant data, Work In Process over the past three periods came in at $7.3 million, $7.5 million, and $7.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.